UK ITP Treatment Update: Quentin Hill on Generic Eltrombopag Access and Guidance
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, has shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag.
Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licensed treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar, and greater use of generic eltrombopag will result in a substantial, multi-million-pound cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP.
However, patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
You can find more information here.
Find more posts on Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team